HC Wainwright Cuts Cognition Therapeutics (NASDAQ:CGTX) Price Target to $5.00

Cognition Therapeutics (NASDAQ:CGTX) had its target price trimmed by HC Wainwright from $6.00 to $5.00 in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Cognition Therapeutics’ Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.28) EPS.

Other research analysts have also recently issued research reports about the stock. Chardan Capital reduced their target price on shares of Cognition Therapeutics from $11.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 21st. Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. Finally, B. Riley raised Cognition Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $1.00 to $1.50 in a report on Thursday, December 19th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Cognition Therapeutics currently has a consensus rating of “Buy” and an average target price of $7.50.

Cognition Therapeutics Stock Performance

Cognition Therapeutics stock opened at $0.44 on Monday. The business’s 50-day simple moving average is $0.57 and its two-hundred day simple moving average is $0.55. The company has a market cap of $18.35 million, a PE ratio of -0.46 and a beta of 1.03. Cognition Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.95.

Cognition Therapeutics (NASDAQ:CGTX) last issued its earnings results on Thursday, March 20th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same quarter in the previous year, the firm posted ($0.27) earnings per share. As a group, analysts predict that Cognition Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Cognition Therapeutics

Several hedge funds have recently modified their holdings of CGTX. BIOS Capital Management LP purchased a new position in shares of Cognition Therapeutics in the 4th quarter valued at about $4,208,000. Voss Capital LP purchased a new stake in shares of Cognition Therapeutics in the fourth quarter valued at approximately $351,000. Sigma Planning Corp raised its stake in shares of Cognition Therapeutics by 211.6% during the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock worth $431,000 after buying an additional 417,300 shares during the period. Virtu Financial LLC purchased a new position in shares of Cognition Therapeutics during the 3rd quarter valued at approximately $27,000. Finally, Two Sigma Investments LP grew its stake in Cognition Therapeutics by 372.2% in the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after acquiring an additional 42,321 shares during the period. 43.35% of the stock is owned by hedge funds and other institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.